Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys.
This study examines the effects of xenografts of microencapsulated bovine chromaffin cells (BCCs) on the rotational behavior of hemiparkinsonian monkey recipients. In addition, it determines the content of monoamine neurotransmitters and their major metabolites in the neostriatum in hemiparkinsonian monkeys. The hemiparkinsonian model in monkeys was induced by a unilateral intracarotid injection of methyl-phenyl-tetrahydropyridine (MPTP). Unencapsulated BCCs, BCCs microencapsulated in alginate-polylysine-alginate (ALA) membranes as well as empty microencapsules were grafted into the neostriatum of the hemiparkinsonian monkeys. Following the transplantation the hemiparkinsonian symptoms subsided and the number of rotations induced by apomorphine decreased for up to nine months in the group of recipients grafted with microencapsulated BCCs, while only a temporary improvement (one month) was detected in the recipients of the unencapsulated BCCs. No change was observed in the recipients of empty microencapsules. Dopamine and its metabolites were found considerably depleted in the MPTP-lesioned side versus the unlesioned side of the neostriatum in the hemiparkinsonian monkeys(P<0.05).
Xue
Y L
YL
Institute of Basic Medical Sciences, PLA General Hospital, Beijing, China.
Wang
Z F
ZF
Zhong
D G
DG
Cui
X
X
Li
X J
XJ
Ma
X J
XJ
Wang
L N
LN
Zhu
K
K
Sun
A M
AM
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000313:Adrenal Medulla / Q000166:cytology / Q000637:transplantation; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001058:Apomorphine / Q000494:pharmacology; D002214:Capsules; D002417:Cattle; D019439:Chromaffin Cells / Q000637:transplantation*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D005260:Female; D006719:Homovanillic Acid / Q000378:metabolism; D008253:Macaca mulatta; D017551:Microdialysis; D017072:Neostriatum / Q000378:metabolism / Q000601:surgery; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000601:surgery*; D013239:Stereotyped Behavior / Q000187:drug effects; D014183:Transplantation, Heterologous / Q000379:methods*
D000978:Antiparkinson Agents; D002214:Capsules; D015102:3,4-Dihydroxyphenylacetic Acid; D001058:Apomorphine; D004298:Dopamine; D006719:Homovanillic Acid